Advertising Survey

We would like your input on how advertising is currently used in the site.

Please take this short survey to help us out.

Hide this message

Voiding Difficulties

This PatientPlus article is written for healthcare professionals so the language may be more technical than the condition leaflets. You may find the abbreviations list helpful.

Urinary continence and micturition are functions which require:

  • The integrity of the organs (bladder, urethra, and voluntary and involuntary sphincters).
  • The integrity of the neural pathways responsible for micturition (parasympathetic), continence (sympathetic), and their control and co-ordination.

Apart from the incontinence associated with vesicovaginal fistulae in women, or overflow incontinence associated with a distended bladder in chronic retention, the three principal clinical forms of incontinence are:

Voiding difficulties causing discomfort on urination, or retention (chronic or acute), are the reflection of an imbalance between bladder contraction and urethral resistance.
The complete list includes the following problems:

  • Stress incontinence.
  • Urge incontinence.
  • Poor flow.
  • Intermittent stream.
  • Incomplete emptying.
  • Straining to void.
  • Hesitancy.
  • Acute retention.
  • Chronic retention.
  • Overflow incontinence.
  • Urinary tract infection (UTI) from residual urine.

Aetiology

  • CNS:
  • Drugs:
  • Obstructive:
  • Bladder overdistension:
    • After epidural for childbirth.
    • Faecal impaction is a cause of retention with overflow.
    • Where detrusor weakness is the cause, there is incomplete bladder emptying with dribbling overflow incontinence.

Investigations

  • Mid-stream specimen of urine (MSU) should always be taken to exclude infection.
  • Ultrasound should be performed for residual urine and bladder wall thickness (>6 mm on transvaginal scan associated with detrusor instability).1
  • Cystourethroscopy is also recommended.
  • Uroflowmetry - a rate of <15 mL/second for a volume of >150 mL is abnormal. This test should be performed before any surgery is contemplated.
  • Urodynamic studies; subtraction cystometry is a subtraction of intra-abdominal pressure from measured intravesical pressure to give detrusor pressure. Intravesical measure is a mix of bladder pressure and intra-abdominal pressure.

Management

This will depend on the cause.

Detrusor instability

  • Avoid caffeine (mild diuretic, detrusor stimulant).
  • Begin bladder training to increase the interval between voiding.
  • Anticholinergic drugs are effective, e.g. oxybutynin; however there may be problems with compliance:2,3,4,5
    • Start with 2.5 mg/12-hourly, increasing slowly up to 5 mg/6-hourly (per 12 hours if elderly).
    • Side-effects include dry mouth, blurred vision, nausea, headache, constipation, diarrhoea and abdominal pain. These are less if modified-release once-daily tablets are used.
    • 30 mg/day of Ditropan XL® may be tolerated (approach this by weekly 5 mg jumps). Tolterodine e.g. 2 mg/12-hourly is also effective, with a lower side-effect profile.
    • In the majority of cases this is successful, but in those where it is not, intravesical therapies have been introduced, e.g. neuromodulation, and alternative drug therapies, e.g. vanilloids, botulinum toxin injection, and surgery.6

Stress incontinence7

  • Pelvic floor muscle physiotherapy may help those with symptoms.
  • Although surgery is commonly performed to alleviate or cure stress incontinence, there are nonsurgical options that might well be explored and tried before a woman undergoes surgery.8
  • Minimally invasive techniques, e.g. tension-free tape, have been shown to be effective and acceptable to the patient.9,10
  • The least drastic treatments are behavioural therapies, chiefly pelvic floor muscle training - Kegel exercises. This method is effective but has the drawback of poor patient compliance.
  • Medical management has included hormone replacement therapy and alpha-adrenergic agonists, but questionable results and intolerable risks have shifted this mode to serotonin-norepinephrine reuptake inhibitors, which have CNS action.
  • Finally, there are urethral occlusive devices, which have poor acceptance owing to side-effects and difficulty of use.

Nocturia

For those with nocturia, desmopressin (unlicensed use) may reduce frequency in those resistant to other treatment.2

Acute retention

This may require catheterisation. A suprapubic catheter should be sited if the catheter will be needed for several days.

  • For persistent conditions, e.g. neurological conditions, self-catheterisation techniques may be learned, e.g. with a LoFric® gel-coated catheter.
  • With detrusor weakness, drugs may relax the urethral sphincter or stimulate the detrusor muscle.
  • Alpha-blockers, e.g. tamsulosin 400 micrograms/24-hourly, relax the bladder neck; diazepam relaxes the sphincter.

Obstructive causes

Operative measures may overcome some of the obstructive causes, e.g. urethrotomy for distal urethral stenosis, but this is uncommon.

  • In approximately one-half of women, the causes of obstructive voiding dysfunction are previous anti-incontinence surgery and pelvic organ prolapse, which will usually lead to a surgical intervention.
  • For men, benign prostate disease is the overwhelming cause of obstructive voiding.
  • Due to its increasing prevalence in the ageing male population, a variety of treatments has been developed, with more on the horizon.11

Recurrent UTI

This is defined as 3 episodes in 12 months.

  • It may benefit from antibiotic prophylaxis. However, there is little evidence to support continuous rather than postcoital dosing.12 There is no evidence that rate of recurrence is affected once prophylaxis has stopped.
  • Topical oestrogens offer some benefit over placebo in postmenopausal women.13
  • Cranberry juice is likely to be beneficial in prevention.14


Document references

  1. Robinson D, Anders K, Cardozo L, et al; Can ultrasound replace ambulatory urodynamics when investigating women with irritative urinary symptoms? BJOG. 2002 Feb;109(2):145-8. [abstract]
  2. No authors listed; Managing incontinence due to detrusor instability. Drug Ther Bull. 2001 Aug;39(8):59-64. [abstract]
  3. Holroyd-Leduc JM, Straus SE; Management of urinary incontinence in women: scientific review. JAMA. 2004 Feb 25;291(8):986-95. [abstract]
  4. Nabi G, Cody JD, Ellis G, et al; Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. Cochrane Database Syst Rev. 2006 Oct 18;(4):CD003781. [abstract]
  5. Roxburgh C, Cook J, Dublin N; Anticholinergic drugs versus other medications for overactive bladder syndrome in adults. Cochrane Database Syst Rev. 2007 Oct 17;(4):CD003190. [abstract]
  6. Freeman RM, Adekanmi OA; Overactive bladder. Best Pract Res Clin Obstet Gynaecol. 2005 Dec;19(6):829-41. Epub 2005 Sep 19. [abstract]
  7. Urinary incontinence: the management of urinary incontinence in women, NICE (2006)
  8. Kielb SJ; Stress incontinence: alternatives to surgery. Int J Fertil Womens Med. 2005 Jan-Feb;50(1):24-9. [abstract]
  9. Moore RD, Gamble K, Miklos JR; Tension-free vaginal tape sling for recurrent stress incontinence after transobturator tape sling failure. Int Urogynecol J Pelvic Floor Dysfunct. 2007 Mar;18(3):309-13. Epub 2006 Jul 26. [abstract]
  10. Sassani P, Aboseif SR; Stress urinary incontinence in women. Curr Urol Rep. 2009 Sep;10(5):333-7. [abstract]
  11. Ellerkmann RM, McBride A; Management of obstructive voiding dysfunction. Drugs Today (Barc). 2003 Jul;39(7):513-40. [abstract]
  12. Albert X, Huertas I, Pereiro II, et al; Antibiotics for preventing recurrent urinary tract infection in non-pregnant women. Cochrane Database Syst Rev. 2004;(3):CD001209. [abstract]
  13. Perrotta C, Aznar M, Mejia R, et al; Oestrogens for preventing recurrent urinary tract infection in postmenopausal Cochrane Database Syst Rev. 2008 Apr 16;(2):CD005131. [abstract]
  14. Jepson RG, Craig JC; Cranberries for preventing urinary tract infections. Cochrane Database Syst Rev. 2008 Jan 23;(1):CD001321. [abstract]

Internet and further reading

Acknowledgements

EMIS is grateful to Dr Hayley Willacy for writing this article. The final copy has passed scrutiny by the independent Mentor GP reviewing team. ©EMIS 2010.
Document ID: 2925
Document Version: 21
Document Reference: bgp1993
Last Updated: 11 Aug 2010
Provide feedback